Abalone Bio

Using our platform and proprietary antibody libraries, we’ve discovered activating antibodies for multiple GPCRs. We’re dedicated to expanding the impact of activating and modulating antibody therapeutics to as many targets and diseases as possible through key partnerships. If you're interested in learning more about how we can work together, reach out, we'd love to hear from you ?? https://lnkd.in/dctN_kup

We love watching the developments in the antibody space. Researchers at Massachusetts Institute of Technology have introduced an innovative computational technique that significantly improves the prediction of antibody structures, specifically targeting the hypervariable regions. This could have profound implications for identifying effective antibody candidates for infectious diseases like SARS-CoV-2, HIV, and more. By leveraging large language models, this approach enhances the ability to accurately predict how antibodies will bind to antigens, streamlining the discovery process and potentially saving millions of dollars in clinical trials. Read the published work here "Learning the language of antibody hypervariability" ?? : https://lnkd.in/dhZiZakm Ft: Rohit Singh, Chiho Im, Yu Qiu, Brian Mackness, Abhinav Gupta, Taylor Joren, Samuel S., Lena Erlach, Maria Wendt, Yves Fomekong Nanfack, Bryan Bryson and Bonnie Berger.

Are you at the Keystone Symposia on Molecular & Cellular Biology? Don't miss our VP of data science & AI Sameer Soi's talk!

It’s a privilege to have Neil Berkley on our Board of Directors! With 20+ years of experience in corporate and business development across big pharma, midsize biotech, and small biotech, Neil has led or supported 30+ deals, several exceeding $1B. Thank you Neil for all your support and guidance!

Are you going to Gordon Research Conferences - Harnessing the Power of Advanced Multimodal Approaches to GPCR Drug Discovery? Don't miss the presentation and poster sessions by Monica Schwartz, PhD, and Raghavender Reddy Gopireddy, PhD. It's a great opportunity to learn more about the work we're doing at Abalone Bio! See you there!

In honor of International Day of Women and Girls in Science, we are shining a spotlight on three female scientists who made major contributions to the antibody field: ? Rosalyn Sussman Yalow: A Nobel laureate, Rosalyn co-developed the radioimmunoassay (RIA) technique, revolutionizing medicine by enabling insulin measurement in human blood plasma. Her work led to significant advances in clinical applications like hormone analysis and HIV detection. ? Teruko Ishizaka: Along with her husband, Kimishige “Kimi” Ishizaka, Teruko discovered the IgE antibody, a central regulator of allergy. Their pioneering work has since impacted treatments for asthma, autoimmune diseases, and more. ? Eva Engvall: Eva developed the enzyme-linked immunosorbent assay (ELISA), a groundbreaking alternative to radioimmunoassays used in clinical diagnostics, from pregnancy tests to disease detection. These women’s perseverance and transformative contributions remind us of the power of resilience in science. Their work continues to inspire scientists everywhere!

In honor of International Day of Women and Girls in Science, we are shining a spotlight on three female scientists who made major contributions to the antibody field: ? Rosalyn Sussman Yalow: A Nobel laureate, Rosalyn co-developed the radioimmunoassay (RIA) technique, revolutionizing medicine by enabling insulin measurement in human blood plasma. Her work led to significant advances in clinical applications like hormone analysis and HIV detection. ? Teruko Ishizaka: Along with her husband, Kimishige “Kimi” Ishizaka, Teruko discovered the IgE antibody, a central regulator of allergy. Their pioneering work has since impacted treatments for asthma, autoimmune diseases, and more. ? Eva Engvall: Eva developed the enzyme-linked immunosorbent assay (ELISA), a groundbreaking alternative to radioimmunoassays used in clinical diagnostics, from pregnancy tests to disease detection. These women’s perseverance and transformative contributions remind us of the power of resilience in science. Their work continues to inspire scientists everywhere!

Check out our CEO/Co-Founder Richard Yu's article in pharmaphorum ?? https://lnkd.in/diXiyK5z ?? "These drugs offer solutions to previously untreatable conditions by modulating biological pathways inaccessible to other drug modalities. By combining traditional antibody engineering, synthetic biology, and advanced computational modelling, researchers are building technologies to find antibodies capable of addressing the most challenging biological targets and complex diseases."

Abalone Bio FAQ time! "Do you measure function *and* binding?" ?? We sure do! ?? ? We measure function not just binding: 100M antibodies at once, 100X more than others. ? We biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.

Successful outcomes are driven by the right partnerships ?? . Our VP of Antibody Discovery Monica Schwartz spoke with News Medical about our experience with Trilobio: "With a Trilobot executing our assays, we greatly reduce human error and both ensure higher consistency and accuracy. Trilobio ensures that our cultures are moved to the correct well and the correct pipette volume every time. Also, the Trilobot can put more samples on a plate than a human, which has increased our testing throughput by 33%." Ft Roya Amini-Naieni Maximilian Schommer Lorenzo D'Amico Aaron Leconte